Fair Value Calculator Fair Value Calculator
EN DE

HERANBA (HERANBA) Fair Value & Analysis

Basic Materials · Market cap ₹7.4B

H HERANBA HERANBA · NSE
Price₹184.48
Fair Value₹37.27
Upside-79.8%
Quality41/100
Watch HERANBA for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹9.79 – ₹80.53

Fair value as of: Jul 3, 2026

From 4 valuation models · updated today

Share price +3.4% over the past month.

Price vs Fair Value (12 months)

₹394.54 ₹157.52 Fair Value ₹37.27 Jul 2025 Jul 2026

12‑month range ₹157.52 – ₹394.54 · fair‑value band ₹9.79 – ₹80.53 · the ₹184.48 price screens above the ₹37.27 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

HERANBA (HERANBA) currently trades at ₹184.48, while our model-based Fair Value estimate is ₹37.27 — implying the stock looks roughly 79.8% overvalued today. We read business quality at 41/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, HERANBA generated revenue of ₹15.9B at a net margin of -4.8%. Revenue declined 4.6% year over year. It earns a return on equity of -9.6%. Net debt stands at ₹5.4B. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹15.9B
Revenue growth (YoY) -4.6%
Net margin -4.8%
Return on equity -9.6%
Free cash flow −₹2.3B FY2026
Operating margin -15.3%
More key figures
EPS (TTM) ₹-19.10
EPS growth (YoY) -63.5%
Net debt ₹5.4B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

HERANBA reported revenue of ₹15.9B in FY2026 versus ₹14.3B in FY2022, a compound +2.7%/yr. Reported net income was −₹764M in FY2026.

Revenue +2.7%/yr
FY22 ₹14.3B
FY23 ₹13.1B
FY24 ₹12.5B
FY25 ₹14.2B
FY26 ₹15.9B
Net income
FY22 ₹1.9B
FY23 ₹1.0B
FY24 ₹349M
FY25 ₹30.7M
FY26 −₹764M

Is HERANBA fairly valued? → Check now

Similar stocks

6 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
Corteva, Inc CTVA $77.46 $39.29 -49%
Nutrien Ltd NTR $68.50 $52.75 -23%
Qinghai Salt Lake Industry Co 000792 ¥30.69 ¥21.26 -31%
CF Industries Holdings C1FI34 R$577.43 R$978.53 +69%
Yara International ASA YAR kr 502.80 kr 695.65 +38%
ICL Group ICL $5.07 $2.88 -43%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is HERANBA (HERANBA) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹37.27 versus a price of ₹184.48 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HERANBA?
Our model-based fair value for HERANBA is ₹37.27 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹184.48.
What is the quality score of HERANBA?
HERANBA has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of HERANBA (HERANBA)?
HERANBA reported trailing-twelve-month revenue of about ₹15.9B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of HERANBA?
The net profit margin of HERANBA is about -4.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.